Cindy Xu

Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study

Andrew B. Lassman, Juan Manuel Sepúlveda-Sánchez, Timothy F. Cloughesy et al. · Zurich Open Repository and Archive (University of Zurich) · 2022 · 76 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Phase (Ph) II safety and efficacy results of a single-arm ph ib/II study of capmatinib (INC280) + gefitinib in patients (pts) with EGFR-mutated (mut), cMET-positive (cMET+) non-small cell lung cancer (NSCLC).

Yi‐Long Wu, Dong‐Wan Kim, Enriqueta Felip et al. · Journal of Clinical Oncology · 2016 · 46 citations

Medicine, Oncology, Pharmacology +13

Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.

Martine Piccart, Shinzaburo Noguchi, Kathleen I. Pritchard et al. · Journal of Clinical Oncology · 2012 · 42 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Safety and benefits of automated red cell depletion‐exchange compared to standard exchange in patients with sickle cell disease undergoing chronic transfusion

Yonah Ziemba, Cindy Xu, Katayoun M. Fomani et al. · Transfusion · 2020 · 23 citations

Medicine, Hematology, Hematology Physiology +16

Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma

Yung Lyou, Jonathan E. Rosenberg, Jean Hoffman‐Censits et al. · Clinical Genitourinary Cancer · 2021 · 20 citations · Full text

Medicine, Oncology, Pharmacology +17